VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Bristol-Myers Squibb Company vs CoStar Group, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisCoStar Group, Inc.
CSGP · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into CoStar Group, Inc.'s moat claims, evidence, and risks.
View CSGP analysisComparison highlights
- Moat score gap: CoStar Group, Inc. leads (75 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); CoStar Group, Inc. has 6 segments (39% in Multifamily (Apartments.com Network)).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; CoStar Group, Inc. has 9 across 4.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
CoStar Group, Inc.
Multifamily (Apartments.com Network)
Online multifamily rental marketplaces and advertising
United States
Two-sided (renters + property managers/owners)
Marketplace (subscription advertising + workflow tools)
39%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
CoStar Group, Inc. strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
CoStar Group, Inc. segments
Full profile >CoStar (commercial real estate info & analytics)
Oligopoly
Information Services (lease management software + international info)
Competitive
Multifamily (Apartments.com Network)
Oligopoly
LoopNet (commercial property marketing marketplace)
Oligopoly
Residential (Homes.com + OnTheMarket)
Oligopoly
Other Marketplaces (Ten-X, Land.com, BizBuySell, etc.)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.